Form 4: Sangamo CEO Macrae Reports RSU Tax Withholding

Sangamo Therapeutics CEO Sandy Macrae reported the surrender of 102,950 shares for mandatory tax withholding related to vested restricted stock units.

Summary

• Sandy Macrae, President, CEO, and Director of Sangamo Therapeutics, Inc. (SGMO), reported a transaction on January 22, 2026.
• The transaction involved the disposition of 102,950 shares of common stock.
• These shares were surrendered solely for mandatory tax withholding purposes, related to the vesting of a restricted stock unit (RSU) grant.
• The shares were valued at the Issuer's closing stock price on January 22, 2026, which was $0.3985 per share.
• This transaction is deemed a disposition for reporting purposes and does not represent a discretionary trade by Mr. Macrae.
• Following this transaction, Mr. Macrae beneficially owns 1,946,584 shares of common stock directly.
• The remaining beneficial ownership includes 147,050 shares from the January 22, 2024 RSU grant (vested January 22, 2026), 14,747 shares from the February 24, 2023 RSU grant vesting quarterly through February 24, 2026, and 375,000 shares from the February 25, 2025 RSU grant, with 1/4 vesting on February 25, 2026, and the remainder in 8 successive equal quarterly installments.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation (tax withholding for vested RSUs). It does not indicate any positive or negative operational or financial performance, nor does it suggest any strategic shifts or market-moving events.

Future Outlook

Future vesting schedules for Sandy Macrae's RSU grants include quarterly installments through February 24, 2026, for a February 24, 2023 grant, and a February 25, 2025 grant with 1/4 vesting on February 25, 2026, and the remainder in 8 successive equal quarterly installments thereafter. All vesting is subject to continuous service.

Industry Context

This filing is a routine disclosure of an insider transaction related to executive compensation, specifically the vesting of restricted stock units and the associated tax withholding. It does not provide information directly related to broader industry trends or competitive positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary compensation-related transaction, not a discretionary sale or purchase indicating management's view on company prospects.
• Employees: Reflects standard executive compensation practices under the company's equity incentive plan.

Next Steps

• Continued vesting of 14,747 shares from the February 24, 2023 RSU grant in successive equal quarterly installments through February 24, 2026.
• Vesting of one-fourth (1/4) of the 375,000 shares from the February 25, 2025 RSU grant on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Tax Withholding, Beneficial Ownership, Executive Compensation